Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273297 | 1.00 | S1PR1 (0.59) | S1PR1MAOAMAOB | |
| SCHEMBL25228663 | 0.81 | MAOB (0.57) | S1PR1MAOAMAOB | |
| SCHEMBL30488247 | 0.81 | MAOB (0.57) | S1PR1MAOAMAOB | |
| SCHEMBL25226963 | 0.74 | S1PR1 (0.63) | S1PR1 | |
| SCHEMBL30488211 | 0.74 | S1PR1 (0.63) | S1PR1 | |
| SCHEMBL31395131 | 0.74 | S1PR1 (0.51) | S1PR1 | |
| SCHEMBL4708272 | 0.73 | MAOB (0.67) | MAOAMAOB | |
| SCHEMBL4815217 | 0.72 | MAOB (0.49) | MAOAMAOB | |
| SCHEMBL26179844 | 0.71 | S1PR1 (0.46) | S1PR1 | |
| SCHEMBL25224654 | 0.71 | MAOB (0.64) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118632834-A | Indanyl compounds containing carboxylic acids for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | S1PR1 4/4885MAOA 2393/4885MAOB 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.